Anaptysbio (ANAB) Shares Outstanding (Diluted Average) (2016 - 2026)
Anaptysbio (ANAB) reported Shares Outstanding (Diluted Average) of $28.7 million for Q1 2026, down 6.37% on a YoY basis from $30.6 million in Q1 2025, and little changed quarter-over-quarter from $28.8 million in Q4 2025.
Anaptysbio (ANAB) Shares Outstanding (Diluted Average) (2016 - 2026) Analysis & Trends
Anaptysbio has reported Shares Outstanding (Diluted Average) for 10 years, with the latest figure at $28.7 million in Q1 2026.
- For the quarter ending Q1 2026, Shares Outstanding (Diluted Average) fell 6.37% year-over-year to $28.7 million; the trailing twelve-month figure through Mar 2026 stood at $28.7 million (down 6.37% YoY), and the FY2025 full-year result was $28.8 million, up 1.32% from the prior year.
- Shares Outstanding (Diluted Average) for Q1 2026 stood at $28.7 million, roughly flat from $28.8 million in the prior quarter.
- The five-year high for Shares Outstanding (Diluted Average) was $30.6 million in Q1 2025, with the low at $26.5 million in Q3 2023.
- Historically, Shares Outstanding (Diluted Average) has averaged $28.0 million across 5 years, with a median of $28.0 million in 2022.
- Annual changes were most pronounced in 2025 — Shares Outstanding (Diluted Average) increased 14.34% — and 2026, when it fell 6.37%.
- Anaptysbio's Shares Outstanding (Diluted Average) stood at $28.2 million in 2022, then retreated by 4.41% to $26.9 million in 2023, then advanced by 5.42% to $28.4 million in 2024, then climbed by 1.32% to $28.8 million in 2025, then decreased by 0.23% to $28.7 million in 2026.
- The last three Shares Outstanding (Diluted Average) figures came in at $28.7 million (Q1 2026), $28.8 million (Q4 2025), and $29.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 4,489.46 Bn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 810.00 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 118.76 Bn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 1.48 Bn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 256.30 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 92.44 Mn |
| 10 | Anaptysbio | 1.66 Bn | 1.38 Bn | - | 28.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 28.69 Mn |
| Dec 31, 2025 | 28.76 Mn |
| Sep 30, 2025 | 29.02 Mn |
| Jun 30, 2025 | 28.81 Mn |
| Mar 31, 2025 | 30.64 Mn |
| Dec 31, 2024 | 28.38 Mn |
| Sep 30, 2024 | 27.69 Mn |
| Jun 30, 2024 | 27.08 Mn |
| Mar 31, 2024 | 26.80 Mn |
| Dec 31, 2023 | 26.92 Mn |
| Sep 30, 2023 | 26.55 Mn |
| Jun 30, 2023 | 26.63 Mn |
| Mar 31, 2023 | 27.95 Mn |
| Dec 31, 2022 | 28.17 Mn |
| Sep 30, 2022 | 28.29 Mn |
| Jun 30, 2022 | 27.96 Mn |
| Mar 31, 2022 | 27.71 Mn |
| Dec 31, 2021 | 27.43 Mn |
| Sep 30, 2021 | 27.44 Mn |
| Jun 30, 2021 | 27.39 Mn |